Protalix BioTherapeutics (FRA:PBDA) Cyclically Adjusted PB Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PBDA Protalix BioTherapeutics Inc FRA:PBDA
56 GF Score
Price €2.00
GF Value €1.89
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Protalix BioTherapeutics  (FRA:PBDA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Protalix BioTherapeutics Cyclically Adjusted PB Ratio Related Terms


Protalix BioTherapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Protalix BioTherapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics Cyclically Adjusted PB Ratio Chart

Protalix BioTherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Protalix BioTherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:PBDA vs GLSI, DTIL, NERV: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:PBDA
56GF Score
Protalix BioTherapeutics Inc FRA:PBDA
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protalix BioTherapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Protalix BioTherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Protalix BioTherapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.769/333.9520*333.9520
=0.769

Current CPI (Jun. 2026) = 333.9520.

Protalix BioTherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 -1.347 241.428 -1.863
201612 -0.760 241.432 -1.051
201703 -5.119 243.801 -7.012
201706 -1.425 244.955 -1.943
201709 -1.634 246.819 -2.211
201712 -1.732 246.524 -2.346
201803 -2.197 249.554 -2.940
201806 -2.864 251.989 -3.796
201809 -3.756 252.439 -4.969
201812 -3.133 251.233 -4.165
201903 -3.570 254.202 -4.690
201906 -4.025 256.143 -5.248
201909 -4.336 256.759 -5.640
201912 -4.265 256.974 -5.543
202003 -0.861 258.115 -1.114
202006 -0.952 257.797 -1.233
202009 -0.848 260.280 -1.088
202012 -0.639 260.474 -0.819
202103 0.268 264.877 0.338
202106 0.070 271.696 0.086
202109 0.004 274.310 0.005
202112 -0.117 278.802 -0.140
202203 -0.147 287.504 -0.171
202206 -0.192 296.311 -0.216
202209 -0.232 296.808 -0.261
202212 -0.187 296.797 -0.210
202303 0.015 301.836 0.017
202306 0.503 305.109 0.551
202309 0.491 307.789 0.533
202312 0.422 306.746 0.459
202403 0.375 312.332 0.401
202406 0.362 314.175 0.385
202409 0.397 315.301 0.420
202412 0.544 315.605 0.576
202503 0.535 319.799 0.559
202506 0.543 322.561 0.562
202509 0.561 324.800 0.577
202512 0.512 324.054 0.528
202603 0.722 330.213 0.730
202606 0.769 333.952 0.769

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for FRA:PBDA:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Protalix BioTherapeutics Business Description

Other Exchanges PLX:USA
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score

Get the complete analysis for FRA:PBDA

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price
€1.89
GF Value